1,720,981 research outputs found
sj-docx-1-msj-10.1177_13524585231195346 – Supplemental material for Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension
No full textSupplemental material, sj-docx-1-msj-10.1177_13524585231195346 for Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension by Stephen L Hauser, Ronald Zielman, Ayan Das Gupta, Jing Xi, Dee Stoneman, Goeril Karlsson, Derrick Robertson, Jeffrey A Cohen and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-1-mso-10.1177_20552173231203816 - Supplemental material for Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis
No full textSupplemental material, sj-docx-1-mso-10.1177_20552173231203816 for Tolerability of subcutaneous ofatumumab with long-term exposure in relapsing multiple sclerosis by John Kramer, Ralf Linker, David Paling, Adam Czaplinski, Olaf Hoffmann, V Wee Yong, Noreen Barker, Amy Perrin Ross, Elisabeth Lucassen, Mohammad Gufran, Xixi Hu, Ronald Zielman, Gustavo Seifer and Patrick Vermersch in Multiple Sclerosis Journal – Experimental, Translational and Clinical</p
sj-docx-11-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-11-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-2-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-2-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-8-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-8-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-6-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-6-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-3-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-3-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-pdf-10-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-pdf-10-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-5-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-5-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
sj-docx-7-msj-10.1177_13524585221079731 – Supplemental material for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years
No full textSupplemental material, sj-docx-7-msj-10.1177_13524585221079731 for Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years by Stephen L Hauser, Anne H Cross, Kevin Winthrop, Heinz Wiendl, Jacqueline Nicholas, Sven G Meuth, Paul S Giacomini, Francesco Saccà, Linda Mancione, Ronald Zielman, Morten Bagger, Ayan Das Gupta, Dieter A Häring, Valentine Jehl, Bernd C Kieseier, Ratnakar Pingili, Dee Stoneman, Wendy Su, Roman Willi and Ludwig Kappos in Multiple Sclerosis Journal</p
- …
